Efficacy and safety of olverembatinib in adult BCR :: ABL1 ‐positive ALL with T315I mutation or relapsed/refractory disease

Documenti analoghi

• CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
  di: Emil Arjun Kumar, et al.
  Pubblicazione: (2024)
• Corrigendum to “Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1 ”
  Pubblicazione: (2024)
• Treatment‐Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients
  di: C. Kockerols, et al.
  Pubblicazione: (2025)
• Efficacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: A single‐centre, retrospective study
  di: Yu‐Han Gao, et al.
  Pubblicazione: (2024)
• PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia
  di: Jaimal Kothari, et al.
  Pubblicazione: (2024)